The Biomedical Division of PHC Corporation has introduced a prototype of LiCellGrow, a cell expansion system designed to optimise cell growth conditions and support the manufacturing process of cell and gene therapy products.
The offering aims to address the growing demand for cell and gene therapies by improving the efficiency and stability of cell production.
Go deeper with GlobalData
LiCellGrow is currently under development to enable pharmaceutical companies to monitor metabolic changes in cells continuously and in real time.
The system will automatically adjust cell culture conditions, potentially expanding the availability of cell and gene therapy products by accelerating the manufacture of specific cells required for these therapies.
Its technology aims to ensure stable cell quality by enabling real-time monitoring and control of the cell culture environment.
LiCellGrow’s In-Line monitoring technology continuously measures cell metabolites in the culture medium without repeated sampling, providing researchers with a visualisation of changes in the culture environment and cell status.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe system measures concentrations of glucose and lactate, key indicators of cell metabolism, and automatically exchanges the culture medium to maintain optimal conditions.
This approach is expected to improve cell quality, increase efficiency and reduce costs through loss reduction.
LiCellGrow will also feature easy-to-install single-use culture bags with In-Line sensors, promoting closed-system cell culturing to maintain sterility.
It can be integrated into existing COâ‚‚ incubators, allowing researchers to use their preferred equipment.
The cell expansion system represents a collaboration between PHC’s biomedical division and IVD [in vitro diagnostics] division, combining advanced sensor technology from IVD with cell culture environment control technology from the biomedical division.
The biomedical division plans to launch LiCellGrow globally in the short term to support the development of manufacturing processes for cell and gene therapy products, and aims to accelerate its development for commercialised production.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
